912556-91-3Relevant articles and documents
Synthesis and biological evaluation of selenogefitinib for reducing bleomycin-induced pulmonary fibrosis
Bai, Yue,Zhang, Yunhao,Chu, Peng,Wang, Changyuan,Li, Lei,Qi, Yan,Han, Xu,Zhang, Baojing,Sun, Huijun,Li, Yanxia,Chen, Lixue,Ma, Xiaodong
, (2021/07/08)
Selenium has demonstrated effectiveness in the reduction of oxidative stress and inflammation in vitro and in vivo, both of which are key indicators of the pathogenesis of pulmonary fibrosis. Gefitinib, an FDA-approved EGFR inhibitor, effectively reverses
N '-aryl-N, N-dimethyl-formamidine new method for the preparation of (by machine translation)
-
Paragraph 0085-0087, (2017/02/17)
The present invention provides a synthetic N '-aryl-N, N-dimethyl-formamidine of the new method. The method firstly to N, N-dimethyl formamide and dimethyl sulfate to imine salt; generating imide salt in the presence of an alkali, and aromatic amine reaction generating N '-aryl-N, N-dimethyl-carboximidamide; the amidines same with other amine function generating [...] compound, can be used in the anti-tumor drug AKT, synthesis of lapatinib and gefitinib, and the like. Mild reaction conditions of the method, is suitable for industrial production. (by machine translation)
AMINOQUINAZOLINE DERIVATIVES AND THEIR SALTS AND METHODS OF USE
-
, (2014/08/19)
The present invention relates to the field of medicine. Provided herein are aminoquinazoline derivatives, their salts and pharmaceutical formulations useful in modulating the protein tyrosine kinase activity, and in modulating inter- and/or intra-cellular signaling. Also provided herein are pharmaceutically acceptable compositions comprising the aminoquinazoline compounds and methods of using the compositions in the treatment of hyperproliferative disorders in mammals, especially humans.